Clinical trials: Assessment
Vulvodynia
Dysport in Vulvodynia Phase II Study
This study is designed to define optimal doses of Dysport and evaluate its efficacy and safety compared with placebo for the treatment of vulvodynia.
- Trial name
- DYVINIA (NCT03598777)
- Testing
- Botulinum toxin type A
- Where
- 9 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Ipsen
HIV Infections, Opioid-Related Disorders
Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users
Drug abuse and HIV/AIDS are serious global health problems. Injection drug use is currently the major mode of transmission of HIV in many countries.
- Trial name
- NCT00270257
- Testing
- Buprenorphine/Naloxone
- Where
- 4 sites in China, Thailand
- Volunteers
- 1,251 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
End-Stage Renal Disease, Secondary Hyperparathyroidism
A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis
The objective is to evaluate the safety of paricalcitol capsules in pediatric subjects, ages 10 to 16 years old, with Stage 5 chronic kidney disease (kidney failure) receiving peritoneal dialysis or hemodialysis and being treated…
- Trial name
- NCT01382212
- Testing
- paricalcitol
- Volunteers
- 13 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Healthy
A Study in Healthy People to Test Whether Different Doses of BI 1015550 Have Potential to Induce Heart Rhythm Abnormalities
The main objective of this trial is to evaluate the effects of a single therapeutic and a single supra-therapeutic dose of BI 1015550 following oral administration on cardiac safety parameters in healthy male and female…
- Trial name
- NCT06107036
- Testing
- BI 1015550, Moxifloxacin
- Where
- United Kingdom
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Major Depressive Disorder, Treatment-Resistant Depression
Antidepressant Effects of TS-161 in Treatment-Resistant Depression
Background: Major depressive disorder (MDD) is a common, chronic mental illness. It can take weeks to months for antidepressants to work. Researchers want to test a new drug that might act more rapidly.
- Conditions
- Major Depressive Disorder, Treatment-Resistant Depression, Depression
- Trial name
- NCT04821271
- Testing
- TS-161
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Mental Health (NIMH)
HIV, Human Immunodeficiency Virus
Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection
This study is a Phase 2b study designed to evaluate the efficacy, safety, and tolerability of PRO 140 monotherapy for the maintenance of viral suppression in subjects who are stable on combination antiretroviral therapy.
- Trial name
- NCT02175680
- Testing
- PRO 140, Historical data
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- CytoDyn, Inc.
Paroxysmal Nocturnal Hemoglobinuria
Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria
This study was designed to provide continued access to BCX9930 for participants with Paroxysmal Nocturnal Hemoglobinuria (PNH) who had benefited from treatment with BCX9930 in another BioCryst-sponsored study for PNH who, in the…
- Trial name
- NCT05741346
- Testing
- BCX9930
- Where
- 11 sites in France, Hungary and 5 more
- Volunteers
- 28 people
- Sponsor
- BioCryst Pharmaceuticals
Insomnia
Efficacy and Safety of Temazepam in HIV Seropositive Patients With Insomnia
The purpose of this study is to test two study drugs, one of which is temazepam (15mg) and one of which is a placebo (an inactive substance that looks just like the temazepam), to see if insomnia (trouble sleeping) can be reduced…
- Trial name
- NCT02153788
- Testing
- Temazepam
- Volunteers
- 44 people
- Sponsor
- Duke University
Hemophilia A
BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A
A study to assess treatment with a new formulation of recombinant factor VIII reconstituted with liposomes (BAY79-4980) to evaluate whether a once-a-week treatment is safe and can prevent bleeds in subjects with severe…
- Trial name
- NCT00623727
- Testing
- rFVIII-FS/pegylated liposomes (BAY79-4980), rFVIII-FS/WFI (BAY14-2222)
- Where
- 95 sites in United States, Argentina and 24 more
- Volunteers
- 143 people
- Sponsor
- Bayer
Healthy
A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People
The purpose of this clinical trial is to learn if the study medicine (called PF-07817883) is safe and how it goes in and out of the body in healthy people. PF-07817883 is for the potential treatment of COVID-19.
- Trial name
- NCT05580003
- Testing
- PF-07817883, Midazolam, Moxifloxacin
- Where
- 2 sites in United States, Belgium
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Pfizer
Carotid Stenosis
Optical Coherence Tomography Angiography Evaluation of Ocular Changes in Patients With Carotid Artery Stenosis
This study aims to evaluate ocular changes in patients with carotid artery stenosis by optical coherence tomography angiography before and after carotid artery revascularization procedure.
- Trial name
- NCT04326842
- Testing
- Carotid artery revascularization procedure, Optical coherence tomography angiography
- Where
- China
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Schizophrenia
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia
The objectives of this 12-week study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia.
- Trial name
- NCT02477670
- Testing
- AVP-786
- Where
- 17 sites in United States
- Volunteers
- 145 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Hypogonadism
A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations
Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a propriety testosterone replacement product, Testosterone MD-Lotion and this study will assess the occurrence of skin safety…
- Trial name
- NCT00857454
- Testing
- Testosterone MD-Lotion
- Where
- 11 sites in United States
- Volunteers
- 71 people
- Sponsor
- Eli Lilly and Company
Respiratory Rate
Respiration Rate V2.0 in a Hospital Setting
The purpose of this study is to meet the respiration rate accuracy specifications for the study pulse oximeter monitoring system (study device) in a hospitalized volunteer population when compared to established technologies for…
- Trial name
- NCT01837537
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Medtronic - MITG
Renal Insufficiency
Renal Safety Evaluation After Dotarem®-Enhanced MRI
Although there is a well documented risk of acute renal failure with the iodinated contrast agents, the implication of intravenous gadolinium-based contrast agents in nephrotoxicity remains controversial.
- Trial name
- RESCUE (NCT00650845)
- Testing
- Dotarem®-enhanced MRI, non-enhanced MRI
- Where
- 15 sites in Belgium, France and 2 more
- Volunteers
- 135 people
- Sponsor
- Guerbet
Exercise-Induced Bronchoconstriction (EIB)
Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)
The primary objective of this study is to evaluate the efficacy of a single dose (2 inhalations, 180 mcg total) of Albuterol SPIROMAX (90 mcg per inhalation) versus placebo in patients with EIB.
- Trial name
- NCT01791972
- Testing
- Albuterol Spiromax
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Blood Loss
Evaluation of the Zynex Blood Volume Monitor in Healthy Adult Patients During a Blood Draw
Non-invasive monitoring to measure changes in blood volume.
- Trial name
- NCT01846195
- Testing
- CM 1500
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Zynex Monitoring Solutions
Asthma
A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA
The purpose of this study is to characterize the safety profile of benralizumab administration in asthma patients who have completed one of the three predecessor studies: D3250C00017, D3250C00018 or D3250C00020.
- Trial name
- BORA (NCT02258542)
- Testing
- Benralizumab
- Where
- 429 sites in United States, Argentina and 22 more
- Volunteers
- 2,133 people
- Sponsor
- AstraZeneca
COVID-19 Pneumonia
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia
This study (EMPACTA) will a) evaluate the efficacy and safety of tocilizumab (TCZ) compared with a placebo in combination with standard of care (SOC) in hospitalized participants with COVID-19 pneumonia, and b) include an…
- Trial name
- EMPACTA (NCT04372186)
- Testing
- Tocilizumab
- Where
- 44 sites in United States, Brazil and 4 more
- Volunteers
- 377 people
- Sponsor
- Genentech, Inc.
COPD
Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD
The study investigates the effect of 3 days of twice daily treatment of two different doses of RPL554 (a phosphodiesterase [PDE]3/4 inhibitor) or placebo, each administered in addition to once daily tiotropium/olodaterol…
- Trial name
- NCT03673670
- Testing
- RPL554 Suspension, Tiotropium/olodaterol (Respimat)
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 79 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA